ClinicalTrials.gg
CompletedNCT01500720Updated Apr 13, 2015Results posted

Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer

A Phase 2 interventional study of Cabazitaxel and Topotecan in Small Cell Lung Cancer, sponsored by Sanofi. Completed at 58 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-04-13.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
179
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 120 studies in Small Cell Lung Carcinoma with a site in France — 30 open to participants now, 53 under way, 17 of them phase 3. Small Cell Lung Carcinoma · France.

Enrollment
63rd of 110
179 · median 198
Started
2012
with 3 others
Phase 2
26 of 120
3 open now
Registered
19th of 120
by date

Among the 120 studies in Small Cell Lung Carcinoma with a site in France, this one is the 63rd largest by enrollment of the 110 interventional ones that give a count, is one of 4 that started in 2012, is one of 26 in phase 2, and was the 19th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

30 of the 120 studies in Small Cell Lung Carcinoma with a site in France are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 120 studies in Small Cell Lung Carcinoma with a site in France, or all of them as a file.
02

Study summary

Primary Objective:

To demonstrate progression free survival (PFS) improvement for cabazitaxel compared to topotecan in participants with sensitive or resistant/refractory small cell lung cancer following a first line platinum based chemotherapy.

Secondary Objectives:

  • To assess disease progression free rate at 12 weeks
  • To assess Response Rate (Response Evaluation Criteria in Solid Tumor [RECIST] 1.1) and duration of response
  • To assess Overall Survival (OS)
  • To assess the Safety (National Cancer Institute - Common Toxicity Criteria [NCI-CTC] version 4.03)
  • To assess the Health-Related Quality of Life (HRQoL)
Read the detailed description

Participants are to be treated until progressive disease, unacceptable toxicity or refusal for further study treatment.

All participants are to be followed for disease progression documentation and for participant status until the study cut-off date.

03

Conditions studied

  • Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological/cytological proven locally advanced or small cell lung cancer with progressive disease during or after platinum based chemotherapy
  • Male or female greater than or equal to (>=) 18 years (or country's legal age of majority if greater than [>]18 years)
  • Participants with , (RECIST) (version 1.1)
  • (ECOG) performance status less than or equal to (\<=) 1

Exclusion criteria

Exclusion criteria:

  • Absence of signed and dated Institutional Review Board (IRB)-approved participant form prior to enrollment into the study
  • More than one prior chemotherapy regimen. Prior treatment with topotecan or taxanes
  • Less than 28 days elapsed from prior treatment with chemotherapy, radiotherapy or surgery to the time of randomization (Radiotherapy for bone pain palliation is allowed)
  • Adverse events (excluding alopecia) from any prior anticancer therapy of grade >1 (National Cancer Institute Common Terminology Criteria [] v4.03) at the time of randomization
  • Uncontrolled Central Nervous System (CNS) : participants with may have previous irradiation, only participants with stable disease or response to irradiation who are without CNS symptoms and on a maximum dose of dexamethasone 8 mg daily or equivalent could be included
  • Participants with known
  • History of other, invasive neoplasm requiring ongoing therapy
  • Participation in another clinical trial and any concurrent treatment with any drug within 30 days prior to randomization
  • Any of the following within 6 months prior to study enrollment: myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, class III or IV congestive heart failure, stroke or
  • Any severe acute or chronic medical condition, which could impair the ability of the participant to participate in the study or interfere with interpretation of study results
  • Known (HIV) disease, or active or C (systematic testing was not required)
  • Pregnant or breast-feeding woman. Positive serum or urine pregnancy test prior to randomization
  • Participant with (M/F) who did not agree to use an accepted and effective method of during the study treatment period and for at least 6 months after the completion of the study treatment. The definition of "effective method of contraception" was based on the investigator's judgment. Effective method of contraception should also be adapted to local regulation
  • History of to polysorbate 80
  • Inadequate organ and bone marrow function as evidenced by:

    • less than [\<] 9.0 gram per deciliter (g/dL)
    • \<1.5 x 10\^9 per liter
    • count \<100 x 10\^9 per liter
    • /Serum Glutamic Oxaloacetic Transaminase (AST/SGOT) and/or alanine aminotransferase/Serum Glutamic-Pyruvic Transaminase (ALT/SGPT) >2.5 x (ULN)
    • Alkaline Phosphatase (AP) >2.5 x ULN. In case of liver metastases AP >5 x ULN
    • Total >1.0 x ULN
    • Serum Creatinine >1.5 x ULN. If creatinine 1.0 - 1.5 x ULN, will be calculated according to Chronic Kidney Disease Epidemiology Collaboration formula, and creatinine clearance \<60 milliliter per minute (mL/min) was exclude the participant.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
179 participants (actual)

Study arms

  • Experimental
    Cabazitaxel

    Drug: Cabazitaxel

  • Active comparator
    Topotecan

    Drug: Topotecan

Interventions

  • Cabazitaxel 25 milligram per square meter (mg/m\^2) intravenously (IV) on Day 1 every 3 weeks (21-day cycle) until unacceptable toxicity, disease progression or withdrawal consent.

    Also known as: XRP6258

  • Topotecan 1.5 mg/m\^2 IV on Day 1 to Day 5 every 3 weeks (21-Day cycle) until unacceptable toxicity, disease progression or withdrawal consent.

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    PFS was defined as the time interval from the date of randomization to the date of occurrence of the first documented tumor progression or death due to any cause, whichever came first. Median PFS was estimated using the Kaplan-Meier method. Progression was defined using Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1) as: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study or unequivocal progression of existing non-target lesion. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeter (mm). The appearance of one or more new lesions is also considered progression.

    Time frame: Randomization to first tumor progression/clinical deterioration or death (maximum 7.6 months)

Secondary outcomes

  1. Overall Survival

    Overall survival was defined as the time interval from the date of randomization to the date of death due to any cause. In the absence of confirmation of death, survival time was to be censored at the last date the participant was known to be alive. Median time was estimated by Kaplan-Meier curve.

    Time frame: From randomization to date of death (maximum 15 months)

  2. Progression Free Rate at Week 12

    Progression was defined using Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1) as: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study or unequivocal progression of existing non-target lesion. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression. Death due to disease progression within 12 weeks without radiological documentation of progressive disease was counted as an event. Percentage of participants who were progression free at week 12 are reported.

    Time frame: Week 12

  3. Overall Objective Tumor Response Rate

    Overall objective tumor response was defined as the proportion of participants with confirmed RECIST 1.1 achieving a complete response (CR) or partial response (PR). CR was defined as disappearance of all target/non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Percentage of participants with overall objective tumor response is reported.

    Time frame: Randomization to disease progression/occurrence (maximum 7.6 months)

07

Results

Posted Apr 13, 2015

Participant flow

Participant flow — Overall Study
MilestoneCabazitaxelTopotecan
Started9089
Treated8988
Completed8580
Not completed59
Withdrew: Randomized but not treated11
Withdrew: Other48

Outcome measures

PrimaryProgression Free Survival (PFS)

PFS was defined as the time interval from the date of randomization to the date of occurrence of the first documented tumor progression or death due to any cause, whichever came first. Median PFS was estimated using the Kaplan-Meier method. Progression was defined using Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1) as: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study or unequivocal progression of existing non-target lesion. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeter (mm). The appearance of one or more new lesions is also considered progression.

Time frame:
Randomization to first tumor progression/clinical deterioration or death (maximum 7.6 months)
Reported as:
Median · months
Progression Free Survival (PFS)
monthsCabazitaxelTopotecan
Progression Free Survival (PFS)1.4 (1.4 to 1.5)3.0 (2.7 to 4.1)
Statistical analysis
  • Cabazitaxel vs Topotecan · Stratified Two-Sided Log-Rank Test · p = <0.0001 (P-value was calculated from stratified two-sided log-rank test, stratifying for brain metastases and lactate dehydrogenase (LDH) level at the time of randomization.) · Cox proportional hazard: 2.169 · 95% CI 1.563 to 3.01Hazard ratio was estimated using a COX Proportional Hazards regression model, stratifying for brain metastases and LDH level at the time of randomization.
SecondaryOverall Survival

Overall survival was defined as the time interval from the date of randomization to the date of death due to any cause. In the absence of confirmation of death, survival time was to be censored at the last date the participant was known to be alive. Median time was estimated by Kaplan-Meier curve.

Time frame:
From randomization to date of death (maximum 15 months)
Reported as:
Median · months
Overall Survival
monthsCabazitaxelTopotecan
Overall Survival5.2 (3.38 to 6.11)6.8 (5.03 to 8.08)
SecondaryProgression Free Rate at Week 12

Progression was defined using Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1) as: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study or unequivocal progression of existing non-target lesion. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression. Death due to disease progression within 12 weeks without radiological documentation of progressive disease was counted as an event. Percentage of participants who were progression free at week 12 are reported.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Progression Free Rate at Week 12
percentage of participantsCabazitaxelTopotecan
Progression Free Rate at Week 1218.9 (11.4 to 28.5)52.8 (41.9 to 63.5)
SecondaryOverall Objective Tumor Response Rate

Overall objective tumor response was defined as the proportion of participants with confirmed RECIST 1.1 achieving a complete response (CR) or partial response (PR). CR was defined as disappearance of all target/non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Percentage of participants with overall objective tumor response is reported.

Time frame:
Randomization to disease progression/occurrence (maximum 7.6 months)
Reported as:
Number · percentage of participants
Overall Objective Tumor Response Rate
percentage of participantsCabazitaxelTopotecan
Overall Objective Tumor Response Rate0 (0.0 to 4.9)10.1 (4.5 to 19.0)

Adverse events

Collected over All Adverse Events (AE) were collected from signature of the informed consent form until 30 days after last study treatment administration (maximum 66 weeks) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cabazitaxel—36/89 (40.4%)67/89 (75.3%)
Topotecan—41/88 (46.6%)75/88 (85.2%)
Most frequent serious events
Showing 10 of 59
Most frequent serious events
EventCabazitaxelTopotecan
Febrile neutropeniaBlood and lymphatic system disorders6/8910/88
ThrombocytopeniaBlood and lymphatic system disorders1/8910/88
PneumoniaInfections and infestations1/896/88
AnaemiaBlood and lymphatic system disorders1/896/88
Disease progressionGeneral disorders6/894/88
Neutropenic infectionInfections and infestations4/895/88
Neutropenic sepsisInfections and infestations3/891/88
HyponatraemiaMetabolism and nutrition disorders3/890/88
NeutropeniaBlood and lymphatic system disorders2/892/88
PancytopeniaBlood and lymphatic system disorders0/892/88
Most frequent other events
Showing 10 of 30
Most frequent other events
EventCabazitaxelTopotecan
FatigueGeneral disorders26/8922/88
DyspnoeaRespiratory, thoracic and mediastinal disorders9/8921/88
NeutropeniaBlood and lymphatic system disorders2/8920/88
AnaemiaBlood and lymphatic system disorders4/8918/88
DiarrhoeaGastrointestinal disorders18/899/88
AstheniaGeneral disorders10/8917/88
Decreased appetiteMetabolism and nutrition disorders16/8913/88
VomitingGastrointestinal disorders15/897/88
ThrombocytopeniaBlood and lymphatic system disorders0/8914/88
NauseaGastrointestinal disorders14/8911/88

Baseline characteristics

Randomized population included all randomized participants, and was analyzed according to the randomized treatment.

Age, Continuous
Age, Continuous(years)CabazitaxelTopotecanTotal
Mean59.9 ± 9.461.6 ± 10.060.7 ± 9.7
Sex: Female, Male
Sex: Female, Male(Participants)CabazitaxelTopotecanTotal
Female272754
Male6362125
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)CabazitaxelTopotecanTotal
Race: Caucasian/White8082162
Race: Black123
Race: Asian/Oriental9413
Race: Other011
Ethnicity: Hispanic437
Ethnicity: Not Hispanic8686172
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(participants)CabazitaxelTopotecanTotal
0311748
15971130
2011
Primary Tumor Site
Primary Tumor Site(participants)CabazitaxelTopotecanTotal
Lungs162036
Right Lung334376
Left Lung402666
Other: Mediastino-Hilar101
Stage at Diagnosis
Stage at Diagnosis(participants)CabazitaxelTopotecanTotal
IIA112
IIB213
IIIA21214
IIIB251540
IV5755112
Unknown358
Number of Organs Involved
Number of Organs Involved(organs)CabazitaxelTopotecanTotal
Mean3.6 ± 1.33.8 ± 1.43.7 ± 1.3
08

Study locations

58 sites
  • Investigational Site Number 840007
    Muscle Shoals, Alabama 35661, United States
  • Investigational Site Number 840005
    Omaha, Nebraska 68114, United States
  • Investigational Site Number 840006
    Lebanon, New Hampshire 03756, United States
  • Investigational Site Number 840003
    Middletown, Ohio 45042, United States
  • Investigational Site Number 840001
    Philadelphia, Pennsylvania 19104, United States
  • Investigational Site Number 076001
    Porto Alegre, 90610-000, Brazil
  • Investigational Site Number 124003
    Montreal, H3T 1E2, Canada
  • Investigational Site Number 124002
    Oshawa, L1G 2B9, Canada
  • Investigational Site Number 124004
    Rimouski, G5L 5T1, Canada
  • Investigational Site Number 124001
    Toronto, M5G 2M9, Canada
  • Investigational Site Number 152001
    Santiago, 8380456, Chile
  • Investigational Site Number 152005
    Santiago, Chile
  • Investigational Site Number 250005
    Brest, 29609, France
  • Investigational Site Number 250004
    Caen Cedex, 14033, France
  • Investigational Site Number 250006
    La Tronche, 38700, France
  • Investigational Site Number 250002
    Lille, 59800, France
  • Investigational Site Number 250003
    Saint-Herblain Cedex, 44805, France
  • Investigational Site Number 250007
    Villejuif Cedex, 94805, France
  • Investigational Site Number 276003
    Großhansdorf, 22927, Germany
  • Investigational Site Number 276006
    Löwenstein, 74245, Germany
  • Investigational Site Number 300005
    Athens, 11522, Greece
  • Investigational Site Number 300003
    Athens, 11527, Greece
  • Investigational Site Number 300001
    Heraklion, 71110, Greece
  • Investigational Site Number 300002
    Thessaloniki, 54629, Greece
  • Investigational Site Number 300004
    Thessaloniki, 57010, Greece
  • Investigational Site Number 348001
    Budapest, 1121, Hungary
  • Investigational Site Number 348004
    Budapest, 1121, Hungary
  • Investigational Site Number 348002
    Budapest, 1125, Hungary
  • Investigational Site Number 348003
    Törökbálint, 2045, Hungary
  • Investigational Site Number 380001
    Genova, 16132, Italy
  • Investigational Site Number 380002
    Livorno, 57123, Italy
  • Investigational Site Number 380005
    Novara, 28100, Italy
  • Investigational Site Number 380004
    Parma, 43100, Italy
  • Investigational Site Number 410001
    Seoul, 120-752, Korea, Republic of
  • Investigational Site Number 410003
    Seoul, 135-710, Korea, Republic of
  • Investigational Site Number 410002
    Seoul, 138-736, Korea, Republic of
  • Investigational Site Number 578001
    Oslo, 0440, Norway
  • Investigational Site Number 578003
    Stavanger, 4011, Norway
  • Investigational Site Number 578002
    Trondheim, 7006, Norway
  • Investigational Site Number 616004
    Gdansk, 80-952, Poland
  • Investigational Site Number 616003
    Lublin, 20-954, Poland
  • Investigational Site Number 616002
    Poznan, 60-569, Poland
  • Investigational Site Number 616001
    Warszawa, 02-781, Poland
  • Investigational Site Number 642003
    Cluj Napoca, 400015, Romania
  • Investigational Site Number 642005
    Cluj-Napoca, 400015, Romania
  • Investigational Site Number 642001
    Craiova, 200385, Romania
  • Investigational Site Number 642002
    Timisoara, Romania
  • Investigational Site Number 643001
    Moscow, 115478, Russian Federation
  • Investigational Site Number 643005
    St-Petersburg, 197758, Russian Federation
  • Investigational Site Number 643006
    Tula, 300053, Russian Federation
  • Investigational Site Number 643003
    Yaroslavl, 150054, Russian Federation
  • Investigational Site Number 724002
    Badalona, 08916, Spain
  • Investigational Site Number 724004
    Barcelona, 08035, Spain
  • Investigational Site Number 724005
    Málaga, 29010, Spain
  • Investigational Site Number 724001
    Valencia, 46026, Spain
  • Investigational Site Number 804002
    Dnipropetrovsk, 49102, Ukraine
  • Investigational Site Number 804004
    Donetsk, 83092, Ukraine
  • Investigational Site Number 804001
    Lviv, 70031, Ukraine
09

References and documents

Publications

  • Beaumont H, Evans TL, Klifa C, Guermazi A, Hong SR, Chadjaa M, Monostori Z. Discrepancies of assessments in a RECIST 1.1 phase II clinical trial - association between adjudication rate and variability in images and tumors selection. Cancer Imaging. 2018 Dec 11;18(1):50. doi: 10.1186/s40644-018-0186-0. PubMed 30537991 ↗
  • Evans TL, Cho BC, Udud K, Fischer JR, Shepherd FA, Martinez P, Ramlau R, Syrigos KN, Shen L, Chadjaa M, Wolf M. Cabazitaxel Versus Topotecan in Patients with Small-Cell Lung Cancer with Progressive Disease During or After First-Line Platinum-Based Chemotherapy. J Thorac Oncol. 2015 Aug;10(8):1221-8. doi: 10.1097/JTO.0000000000000588. PubMed 26200278 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2012, a primary completion of Apr 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2015, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2011
First posted
Dec 28, 2011
Start
Mar 2012
Primary completionActual
Apr 2014
CompletionActual
Apr 2014
Results first posted
Apr 13, 2015
Last update
Apr 13, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01500720
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Dec 28, 2011
Start date
Mar 2012
Primary completion
Apr 2014
Completion
Apr 2014
Results posted
Apr 13, 2015
Last update
Apr 13, 2015

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cabazitaxel

Start the discussion